| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 394 | 2017 |
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 247 | 2016 |
| Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ... Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017 | 233 | 2017 |
| MYC dysregulation in the progression of multiple myeloma K Misund, N Keane, CK Stein, YW Asmann, G Day, S Welsh, SA Van Wier, ... Leukemia 34 (1), 322-326, 2020 | 155 | 2020 |
| Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control C Pawlyn, MD Bright, AF Buros, CK Stein, Z Walters, LI Aronson, ... Blood cancer journal 7 (3), e549-e549, 2017 | 117 | 2017 |
| Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat CK Stein, P Qu, J Epstein, A Buros, A Rosenthal, J Crowley, G Morgan, ... BMC bioinformatics 16, 1-9, 2015 | 109 | 2015 |
| Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ... Blood cancer journal 7 (2), e535-e535, 2017 | 79 | 2017 |
| Clinical value of molecular subtyping multiple myeloma using gene expression profiling N Weinhold, CJ Heuck, A Rosenthal, S Thanendrarajan, CK Stein, ... Leukemia 30 (2), 423-430, 2016 | 78 | 2016 |
| Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy EW Meermeier, SJ Welsh, ME Sharik, MT Du, VM Garbitt, DL Riggs, ... Blood cancer discovery 2 (4), 354-369, 2021 | 70 | 2021 |
| Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis X Papanikolaou, S Johnson, T Garg, E Tian, R Tytarenko, Q Zhang, ... Oncotarget 5 (12), 4118, 2014 | 52 | 2014 |
| Genomic classification and individualized prognosis in multiple myeloma F Maura, AR Rajanna, B Ziccheddu, AM Poos, A Derkach, K Maclachlan, ... Journal of Clinical Oncology 42 (11), 1229-1240, 2024 | 49 | 2024 |
| Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma JR Sawyer, E Tian, JD Shaughnessy Jr, J Epstein, CM Swanson, ... Leukemia 31 (3), 637-644, 2017 | 40 | 2017 |
| Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression M Chesi, CK Stein, VM Garbitt, ME Sharik, YW Asmann, M Bergsagel, ... Blood cancer discovery 1 (1), 68-81, 2020 | 36 | 2020 |
| Identification of PIKfyve kinase as a target in multiple myeloma CB De Campos, YX Zhu, N Sepetov, S Romanov, LA Bruins, CX Shi, ... Haematologica 105 (6), 1641, 2019 | 35 | 2019 |
| Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, ... Blood cancer journal 6 (7), e453-e453, 2016 | 33 | 2016 |
| The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma CK Stein, C Pawlyn, S Chavan, L Rasche, N Weinhold, A Corken, A Buros, ... Oncotarget 8 (17), 27854, 2017 | 31 | 2017 |
| Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021; 2: 354–369. doi: 10.1158/2643-3230 EW Meermeier, SJ Welsh, ME Sharik, MT Du, VM Garbitt, DL Riggs, ... this study, the authors provide evidence that anti-BCMA/CD3 leads to T-cell …, 2021 | 18 | 2021 |
| ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma P Neri, BG Barwick, D Jung, JC Patton, R Maity, I Tagoug, CK Stein, ... Blood cancer discovery 5 (1), 56-73, 2024 | 17 | 2024 |
| Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma SJ Welsh, BG Barwick, EW Meermeier, DL Riggs, CX Shi, YX Zhu, ... Blood cancer discovery 5 (1), 34-55, 2024 | 17 | 2024 |
| Search for rare protein altering variants influencing susceptibility to multiple myeloma M Scales, D Chubb, SE Dobbins, DC Johnson, N Li, MJ Sternberg, ... Oncotarget 8 (22), 36203, 2017 | 16 | 2017 |